On the other hand, chronic use of ICS also accompanied by potential adverse events, especially in asthmatic patients, including but not limited to blood glucose variation, osteoporosis, oropharyngeal fungal infections and pneumonia46, which forces clinicians to investigate novel medications to resist the adverse events caused by long-term use of β2AR agonists. This evidence concerns the gene ADRB2 and osteoporosis.